Compare Summit Therapeutics Inc (SMMT) vs Under Armour Inc Class A (UA) Price & Performance

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.

Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $201.27 million in fiscal 2025, with negative margins and cash flow, though revenue remains substantial at $5.16 billion. Recent news highlights a new Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.

Outlook is mixed: analyst consensus leans slightly bullish with 40% buy ratings, but fundamental challenges persist including declining revenue projections and negative profitability. Key risks include execution of the business reset and competitive pressures. The stock presents a turnaround opportunity but requires careful monitoring of earnings and margin improvements.